203 related articles for article (PubMed ID: 17040473)
1. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system.
Palazzo E; de Novellis V; Petrosino S; Marabese I; Vita D; Giordano C; Di Marzo V; Mangoni GS; Rossi F; Maione S
Eur J Neurosci; 2006 Oct; 24(7):2011-20. PubMed ID: 17040473
[TBL] [Abstract][Full Text] [Related]
2. Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices.
Mendiguren A; Pineda J
Br J Pharmacol; 2009 Nov; 158(6):1579-87. PubMed ID: 19845674
[TBL] [Abstract][Full Text] [Related]
3. Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat.
de Novellis V; Mariani L; Palazzo E; Vita D; Marabese I; Scafuro M; Rossi F; Maione S
Neuroscience; 2005; 134(1):269-81. PubMed ID: 15953687
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.
Zaniewska M; McCreary AC; Przegaliński E; Filip M
Eur J Pharmacol; 2006 Jul; 540(1-3):96-106. PubMed ID: 16730696
[TBL] [Abstract][Full Text] [Related]
5. Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation.
Makwana R; Molleman A; Parsons ME
Br J Pharmacol; 2010 Jun; 160(3):615-26. PubMed ID: 20590566
[TBL] [Abstract][Full Text] [Related]
6. Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model.
Palazzo E; Luongo L; Bellini G; Guida F; Marabese I; Boccella S; Rossi F; Maione S; de Novellis V
CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):148-61. PubMed ID: 22483283
[TBL] [Abstract][Full Text] [Related]
7. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.
Gómez R; Navarro M; Ferrer B; Trigo JM; Bilbao A; Del Arco I; Cippitelli A; Nava F; Piomelli D; Rodríguez de Fonseca F
J Neurosci; 2002 Nov; 22(21):9612-7. PubMed ID: 12417686
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model.
Haranishi Y; Hara K; Terada T
Pharmacol Rep; 2021 Jun; 73(3):820-827. PubMed ID: 33783763
[TBL] [Abstract][Full Text] [Related]
9. Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition.
Ho YC; Lee HJ; Tung LW; Liao YY; Fu SY; Teng SF; Liao HT; Mackie K; Chiou LC
J Neurosci; 2011 Oct; 31(41):14600-10. PubMed ID: 21994376
[TBL] [Abstract][Full Text] [Related]
10. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.
Mitchell VA; Greenwood R; Jayamanne A; Vaughan CW
Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1186-90. PubMed ID: 17880375
[TBL] [Abstract][Full Text] [Related]
11. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors.
Maione S; Bisogno T; de Novellis V; Palazzo E; Cristino L; Valenti M; Petrosino S; Guglielmotti V; Rossi F; Di Marzo V
J Pharmacol Exp Ther; 2006 Mar; 316(3):969-82. PubMed ID: 16284279
[TBL] [Abstract][Full Text] [Related]
12. CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception.
Hasanein P; Parviz M; Keshavarz M; Javanmardi K
Clin Exp Pharmacol Physiol; 2007; 34(5-6):439-49. PubMed ID: 17439413
[TBL] [Abstract][Full Text] [Related]
13. Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens.
Sperlágh B; Windisch K; Andó RD; Sylvester Vizi E
Neurochem Int; 2009 Jun; 54(7):452-7. PubMed ID: 19428788
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoids suppress excitatory synaptic transmission to dorsal raphe serotonin neurons through the activation of presynaptic CB1 receptors.
Haj-Dahmane S; Shen RY
J Pharmacol Exp Ther; 2009 Oct; 331(1):186-96. PubMed ID: 19592666
[TBL] [Abstract][Full Text] [Related]
15. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Ferrer B; Asbrock N; Kathuria S; Piomelli D; Giuffrida A
Eur J Neurosci; 2003 Sep; 18(6):1607-14. PubMed ID: 14511339
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon.
Storr M; Sibaev A; Marsicano G; Lutz B; Schusdziarra V; Timmermans JP; Allescher HD
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G110-7. PubMed ID: 12893627
[TBL] [Abstract][Full Text] [Related]
17. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
18. Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal.
Mannucci C; Navarra M; Pieratti A; Russo GA; Caputi AP; Calapai G
Nicotine Tob Res; 2011 Apr; 13(4):239-47. PubMed ID: 21324836
[TBL] [Abstract][Full Text] [Related]
19. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
Sagar DR; Jhaveri MD; Richardson D; Gray RA; de Lago E; Fernández-Ruiz J; Barrett DA; Kendall DA; Chapman V
Eur J Neurosci; 2010 Apr; 31(8):1414-22. PubMed ID: 20384778
[TBL] [Abstract][Full Text] [Related]
20. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide].
La Rana G; Russo R; Campolongo P; Bortolato M; Mangieri RA; Cuomo V; Iacono A; Raso GM; Meli R; Piomelli D; Calignano A
J Pharmacol Exp Ther; 2006 Jun; 317(3):1365-71. PubMed ID: 16510698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
